Moderna Shares Drop 3% After FDA Declines Review of New mRNA Flu Vaccine
Moderna’s shares fell 3% after the FDA refused to review its supplemental BLA for the new mRNA flu vaccine, citing insufficient immunogenicity and manufacturing data. The decision delays the company’s plans to launch the vaccine for the 2026–27 flu season and pressures near-term valuation.
1. FDA Decision Rationale
The FDA declined to file Moderna’s supplemental BLA for its experimental mRNA flu vaccine, citing insufficient immunogenicity data from Phase II trials and lack of validated manufacturing process controls. Agency feedback indicated a need for expanded clinical datasets and improved quality assurances before acceptance.
2. Share Price Impact
Moderna’s stock fell about 3% intraday following the announcement, erasing roughly $1.2 billion in market capitalization. Trading volumes surged as investors digested the setback to the company’s second major mRNA vaccine program after COVID-19.
3. Implications for Vaccine Timeline
The FDA’s refusal to review pushes back Moderna’s target launch beyond the 2026–27 flu season, as additional immunogenicity and process validation studies are required. The company plans to conduct these studies and aims to resubmit the application in the third quarter of calendar 2026.